Future of anticoagulant therapy

Cardiovascular Therapeutics
J Harenberg, Martin Wehling

Abstract

Prophylaxis and treatment of thromboembolic diseases is one of the main targets in medicine. Side effects and the necessity of dose adjustment limit the administration of coumarins and unfractionated heparin. Coumarins are therefore underused specially in the elderly population. Low-molecular-weight heparins, heparinoids, and direct thrombin inhibitors have overcome some of the limitations but they all have to be administered systemically. Synthetic systemically indirect and orally to apply direct factor Xa inhibitors and direct thrombin inhibitors are under development. They all aim to improve the underuse and the benefit/risk ratio for anticoagulant therapy. This overview describes the results of the recent studies of these inhibitors of blood coagulation. The future of the new anticoagulants will depend on the demonstration of their safety, efficacy, and health cost savings compared to the conventional antithrombotics.

References

Feb 11, 2005·JAMA : the Journal of the American Medical Association·Victor Gurewich
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·J H AlexanderUNKNOWN XaNADU-ACS INVESTIGATORS
Mar 24, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·William M LeeSunita Sheth
Jun 1, 2005·Drug Discovery Today·Martin de KortConstant A A van Boeckel
Nov 25, 2005·Current Pharmaceutical Design·Lori-Ann Linkins, Jeffrey I Weitz
Dec 27, 2005·Current Topics in Medicinal Chemistry·Eddine Saiah, Chris Soares
Jan 18, 2006·European Journal of Clinical Pharmacology·Job HarenbergChristel Weiss
Jul 25, 2006·Expert Opinion on Investigational Drugs·Dagmar Kubitza, Sylvia Haas
Aug 1, 2007·Circulation·Jack HirshJohn W Eikelboom
Sep 15, 2007·The New England Journal of Medicine·UNKNOWN van Gogh InvestigatorsGary E Raskob
Sep 15, 2007·The New England Journal of Medicine·UNKNOWN van Gogh InvestigatorsGary E Raskob
Jun 11, 2008·Journal of Thrombosis and Haemostasis : JTH·UNKNOWN Botticelli Investigators, Writing CommitteA Segers
Aug 13, 2008·Current Opinion in Hematology·Kenneth A Bauer
Feb 14, 2009·Seminars in Thrombosis and Hemostasis·Job Harenberg
Apr 15, 2009·Cerebrovascular Diseases·Joan Martí-Fàbregas, José Mateo
Aug 7, 2009·The New England Journal of Medicine·Michael Rud LassenRonald J Portman
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Nov 3, 2009·Blood·David GarciaMark A Crowther
Nov 6, 2009·Thrombosis and Haemostasis·Job Harenberg
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
Jan 1, 2010·The New England Journal of Medicine·Donald Stuart Houston, Ryan Zarychanski
Jul 27, 2010·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·F W A Verheugt

❮ Previous
Next ❯

Citations

Jun 16, 2012·Expert Review of Clinical Pharmacology·Stephen B Duffull
Sep 28, 2017·Biomacromolecules·Ho Yong CheongAndrew K Udit

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.